Merck Wnt first, Surrozen goes next in AMD, DME
As advances are made by bustling drug developers at work in the Wingless-related integration site (Wnt) pathway, other research is yielding new discoveries as well. Among the closely watched industry players in Wnt are Boehringer Ingelheim GmbH, Merck & Co. Inc., and Surrozen Inc.
RO
randy osborne
via Bioworld
Updated 1h ago
Source Verification
Corroboration Score: 1This story was independently reported by 1 sources. Click any source to read the original article.
Comments
0 commentsBe respectful and constructive.
Loading comments...
Previous
What the heck are anti-aging peptides, and why does everyone keep talking about them?
Next
Statue would be ‘seal of approval’ for Dungarvan’s famous surfers
Related Articles
ScienceRussian Orbital Station's deployment in new orbit scheduled for 2030-2034 - chief designer
Unknown-8h ago-1 sources
ScienceMMRI to host third annual Lupus Walk
Romesentinel-13h ago-1 sources
Science'Audible screams of delight' from NASA scientists over micrometeorite impacts on the moon witnessed by Artemis 2 astronauts
Space-13h ago-1 sources